Niagen Bioscience, Inc. — Director's Dealing 2010

May 26, 2010

SEC Form 4/A — Form 4/A

Issuer: ChromaDex Corp. (CDXC.OB)
CIK: 0001386570
Period of Report: 2010-05-20

Reporting Person: Varvaro Thomas C (CFO, Secretary)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Employee Stock Options (right to buy)	$1.545	2020-05-20	Common Stock (614250)	614250	Direct
Employee Stock Options (right to buy)	$1.545	2020-05-20	Common Stock (614250)	614250	Direct
Employee Stock Options (right to buy)	$1.545	2020-05-20	Common Stock (200000)	200000	Direct
Employee Stock Options (right to buy)	$1.545	2020-05-20	Common Stock (200000)	200000	Direct
Employee Stock Options (right to buy)	$1.545	2020-05-20	Common Stock (75000)	75000	Direct

Footnotes

F1: This amendment is being filed to correct a Form 4 filed by the Reporting Person on May 24, 2010 with respect to dates exercisable and expiration dates of options granted on May 20, 2010.

F2: Options vest 33 1/3% over three years beginning on May 20, 2011.

F3: Options vest 33 1/3% over three years beginning May 20, 2011; provided further that, these options are only exercisable based on the percentage of warrants exercised as of such vesting date that were issued under that certain Subscription Agreement, dated as of April 22, 2010, between the Issuer and the subscribers named therein. Specifically, if 25% to 49.9% of such warrants have been exercised, then 25% of these options are exercisable; if 40% to 74.9% of such warrants have been exercised, then 50% of these options are exercisable; and if 75% or more of such warrants have been exercised, then 100% of these options are exercisable.

F4: Options vest over four years with cliff vesting of 25% on May 20, 2011 and 1/36 of the total vesting per month over the remaining three years.